A PHASE III, Randomized, Double-Blind, Placebo-Controlled study evaluating the efficacy and safety of GDC-0077 Plus Palbociclib and Fulvestrant Vs Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-mutant, Hormone Resceptor Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research